[ad_1]
Rauch A, Haakonsson AK, Madsen JGS, Larsen M, Forss I, Madsen MR, et al. Osteogenesis is determined by commissioning of a community of stem cell transcription elements that act as repressors of adipogenesis. Nat Genet. 2019;51(4):716–27.
Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Sort 2 diabetes and osteoporosis: a information to optimum administration. J Clin Endocrinol Metab. 2017;102(10):3621–34.
Compston J. Sort 2 diabetes mellitus and bone. J Intern Med. 2018;283(2):140–53.
Jiao H, Xiao E, Graves DT. Diabetes and its impact on bone and fracture therapeutic. Curr Osteoporos Rep. 2015;13(5):327–35.
Hu Z, Ma C, Liang Y, Zou S, Liu X. Osteoclasts in bone regeneration beneath kind 2 diabetes mellitus. Acta Biomater. 2019;84:402–13.
Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N. Results of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol. 2006;84(1):93–101.
Hamann C, Goettsch C, Mettelsiefen J, Henkenjohann V, Rauner M, Hempel U, et al. Delayed bone regeneration and low bone mass in a rat mannequin of insulin-resistant kind 2 diabetes mellitus is because of impaired osteoblast operate. Am J Physiol Endocrinol Metab. 2011;301(6):E1220–8.
Marin C, Luyten FP, Van der Schueren B, Kerckhofs G, Vandamme Ok. The influence of kind 2 diabetes on bone fracture therapeutic. Entrance Endocrinol (Lausanne). 2018;9:6.
Garcia-Garcia A, de Castillejo CL, Mendez-Ferrer S. BMSCs and hematopoiesis. Immunol Lett. 2015;168(2):129–35.
Gomez-Barrena E, Rosset P, Gebhard F, Hernigou P, Baldini N, Rouard H, et al. Feasibility and security of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells related to biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials. 2019;196:100–8.
Guo Y, Xie C, Li X, Yang J, Yu T, Zhang R, et al. Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis. Nat Commun. 2017;8:15621.
Bjorge IM, Kim SY, Mano JF, Kalionis B, Chrzanowski W. Extracellular vesicles, exosomes and shedding vesicles in regenerative medication – a brand new paradigm for tissue restore. Biomater Sci. 2017;6(1):60–78.
Kourembanas S. Exosomes: automobiles of intercellular signaling, biomarkers, and vectors of cell remedy. Annu Rev Physiol. 2015;77:13–27.
Toh WS, Lai RC, Hui JHP, Lim SK. MSC exosome as a cell-free MSC remedy for cartilage regeneration: Implications for osteoarthritis therapy. Semin Cell Dev Biol. 2017;67:56–64.
Zhu Y, Jia Y, Wang Y, Xu J, Chai Y. Impaired bone regenerative impact of exosomes derived from bone marrow mesenchymal stem cells in kind 1 diabetes. Stem Cells Transl Med. 2019;8(6):593–605.
Liu X, Yang Y, Li Y, Niu X, Zhao B, Wang Y, et al. Integration of stem cell-derived exosomes with in situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale. 2017;9(13):4430–8.
Kishore R, Khan M. Cardiac cell-derived exosomes: altering face of regenerative biology. Eur Coronary heart J. 2017;38(3):212–5.
Qin Y, Wang L, Gao Z, Chen G, Zhang C. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast exercise and differentiation in vitro and promote bone regeneration in vivo. Sci Rep. 2016;6:21961.
Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine exercise. Circ Res. 2011;109(7):724–8.
Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman LJ, et al. Reassessment of exosome composition. Cell. 2019;177(2):428–45.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and performance. Cell. 2004;116(2):281–97.
Brennecke J, Stark A, Russell RB, Cohen SM. Rules of microRNA-target recognition. PLoS Biol. 2005;3(3):e85.
Ameres SL, Martinez J, Schroeder R. Molecular foundation for goal RNA recognition and cleavage by human RISC. Cell. 2007;130(1):101–12.
Li D, Liu J, Guo B, Liang C, Dang L, Lu C, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016;7:10872.
Xu R, Shen X, Si Y, Fu Y, Zhu W, Xiao T, et al. MicroRNA-31a-5p from getting older BMSCs hyperlinks bone formation and resorption within the aged bone marrow microenvironment. Growing older Cell. 2018;17(4):e12794.
Wu J, Kuang L, Chen C, Yang J, Zeng WN, Li T, et al. miR-100-5p-abundant exosomes derived from infrapatellar fats pad MSCs shield articular cartilage and ameliorate gait abnormalities by way of inhibition of mTOR in osteoarthritis. Biomaterials. 2019;206:87–100.
Min Z, Zhang R, Yao J, Jiang C, Guo Y, Cong F, et al. MicroRNAs related to osteoarthritis in a different way expressed in bone matrix gelatin (BMG) rat mannequin. Int J Clin Exp Med. 2015;8(1):1009–17.
Xu G, Liu Ok, Anderson J, Patrene Ok, Lentzsch S, Roodman GD, et al. Expression of XBP1s in bone marrow stromal cells is important for myeloma cell progress and osteoclast formation. Blood. 2012;119(18):4205–14.
Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between irritation and Sort 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;99(2):85–92.
Donath MY, Dinarello CA, Mandrup-Poulsen T. Focusing on innate immune mediators in kind 1 and kind 2 diabetes. Nat Rev Immunol. 2019;19(12):734–46.
Notsu M, Yamaguchi T, Okazaki Ok, Tanaka Ok, Ogawa N, Kanazawa I, et al. Superior glycation finish product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by rising TGF-beta expression and secretion. Endocrinology. 2014;155(7):2402–10.
Yang Ok, Wang XQ, He YS, Lu L, Chen QJ, Liu J, et al. Superior glycation finish merchandise induce chemokine/cytokine manufacturing by way of activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol. 2010;9:66.
Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, et al. Superior glycation end-products attenuate human mesenchymal stem cells and forestall cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005;20(9):1647–58.
Claes L, Recknagel S, Ignatius A. Fracture therapeutic beneath wholesome and inflammatory circumstances. Nat Rev Rheumatol. 2012;8(3):133–43.
Alblowi J, Kayal RA, Siqueira M, McKenzie E, Krothapalli N, McLean J, et al. Excessive ranges of tumor necrosis factor-alpha contribute to accelerated lack of cartilage in diabetic fracture therapeutic. Am J Pathol. 2009;175(4):1574–85.
Liu X, Li Q, Niu X, Hu B, Chen S, Tune W, et al. Exosomes secreted from human-induced pluripotent stem cell-derived mesenchymal stem cells forestall osteonecrosis of the femoral head by selling angiogenesis. Int J Biol Sci. 2017;13(2):232–44.
Chen B, Li Q, Zhao B, Wang Y. Stem cell-derived extracellular vesicles as a novel potential therapeutic device for tissue restore. Stem Cells Transl Med. 2017;6(9):1753–8.
Hao ZC, Lu J, Wang SZ, Wu H, Zhang YT, Xu SG. Stem cell-derived exosomes: a promising technique for fracture therapeutic. Cell Prolif. 2017;50:5.
Su T, Xiao Y, Xiao Y, Guo Q, Li C, Huang Y, et al. Bone marrow mesenchymal stem cells-derived exosomal MiR-29b-3p regulates aging-associated insulin resistance. ACS Nano. 2019;13(2):2450–62.
Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Search engine marketing JB, et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell. 2017;171(2):372–84.
Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells towards a pro-metastatic phenotype by MET. Nat Med. 2012;18(6):883–91.
Ying W, Gao H, Dos Reis FCG, Bandyopadhyay G, Ofrecio JM, Luo Z, et al. MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in overweight mice. Cell Metab. 2021;33(4):781–90.
Valadi H, Ekstrom Ok, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated switch of mRNAs and microRNAs is a novel mechanism of genetic alternate between cells. Nat Cell Biol. 2007;9(6):654–9.
Zhang Y, Xie RL, Croce CM, Stein JL, Lian JB, van Wijnen AJ, et al. A program of microRNAs controls osteogenic lineage development by focusing on transcription issue Runx2. Proc Natl Acad Sci USA. 2011;108(24):9863–8.
Li Z, Hassan MQ, Volinia S, van Wijnen AJ, Stein JL, Croce CM, et al. A microRNA signature for a BMP2-induced osteoblast lineage dedication program. Proc Natl Acad Sci USA. 2008;105(37):13906–11.
Schaap-Oziemlak AM, Raymakers RA, Bergevoet SM, Gilissen C, Jansen BJ, Adema GJ, et al. MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev. 2010;19(6):877–85.
Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, et al. Circulating microRNAs as biomarkers in sufferers with allergic rhinitis and bronchial asthma. J Allergy Clin Immunol. 2016;137(5):1423–32.
Salazar-Roa M, Trakala M, Alvarez-Fernandez M, Valdes-Mora F, Zhong C, Munoz J, et al. Transient publicity to miR-203 enhances the differentiation capability of established pluripotent stem cells. EMBO J. 2020;39(16):e104324.
Xie Y, Chen Y, Zhang L, Ge W, Tang P. The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling. J Cell Mol Med. 2017;21(5):1033–41.
Gandla J, Lomada SK, Lu J, Kuner R, Bali KK. miR-34c-5p features as pronociceptive microRNA in most cancers ache by focusing on Cav23 containing calcium channels. Ache. 2017;158(9):1765–79.
Fu YC, Zhao SR, Zhu BH, Guo SS, Wang XX. MiRNA-27a-3p promotes osteogenic differentiation of human mesenchymal stem cells by focusing on ATF3. Eur Rev Med Pharmacol Sci. 2019;23(3 Suppl):73–80.
Pando R, Even-Zohar N, Shtaif B, Edry L, Shomron N, Phillip M, et al. MicroRNAs within the progress plate are conscious of dietary cues: affiliation between miR-140 and SIRT1. J Nutr Biochem. 2012;23(11):1474–81.
Takahara S, Lee SY, Iwakura T, Oe Ok, Fukui T, Okumachi E, et al. Altered expression of microRNA throughout fracture therapeutic in diabetic rats. Bone Joint Res. 2018;7(2):139–47.
Waki T, Lee SY, Niikura T, Iwakura T, Dogaki Y, Okumachi E, et al. Profiling microRNA expression throughout fracture therapeutic. BMC Musculoskelet Disord. 2016;17:83.
Bartel DP. MicroRNAs: goal recognition and regulatory features. Cell. 2009;136(2):215–33.
Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, et al. Semaphorin 4D correlates with elevated bone resorption, hypercalcemia, and illness stage in newly identified sufferers with a number of myeloma. Blood Most cancers J. 2018;8(5):42.
Deb Roy A, Yin T, Choudhary S, Rodionov V, Pilbeam CC, Wu YI. Optogenetic activation of Plexin-B1 reveals contact repulsion between osteoclasts and osteoblasts. Nat Commun. 2017;8:15831.
Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473–80.
Wang N, Liu X, Shi L, Liu Y, Guo S, Liu W, et al. Identification of a chronic motion molecular GLP-1R agonist for the therapy of femoral defects. Biomater Sci. 2020;8(6):1604–14.
[ad_2]
